

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Sandoz Canada Inc. and Teva Canada Limited that the shortages for Sandoz Quetiapine XRT 300 mg Extended-Release Tablet (DIN 02407728) and Teva-Quetiapine XRT 300 mg Extended-Release Tablet (DIN 02395479) respectively have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **February 26, 2018**.

QUETIAPINE FUMARATE

300 MG EXTENDED-RELEASE TABLET

| | | | |
|-------------|-----------------------|-----|-----------|
| 00002407728 | SANDOZ QUETIAPINE XRT | SDZ | \$ 1.5440 |
| 00002395479 | TEVA-QUETIAPINE XR | TEV | \$ 1.5440 |
| 00002300206 | SEROQUEL XR | AZC | \$ 3.9101 |

Alberta Blue Cross has been advised by Sandoz Canada Inc. and Mylan Pharmaceuticals ULC that the shortages for Jencycla 0.35 mg (28 Day) Tablet (DIN 02441306) and Movisse 0.35 mg (28 Day) Tablet (DIN 02410303) respectively have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 9, 2018**.

NORETHINDRONE

0.35 MG TABLET

| | | | |
|-------------|-------------------|-----|-----------|
| 00002441306 | JENCYCLA (28 DAY) | SDZ | \$ 0.3925 |
| 00002410303 | MOVISSE (28 DAY) | MYP | \$ 0.3925 |
| 00000037605 | MICRONOR (28 DAY) | JAI | \$ 0.8654 |

... continued from previous page

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Ratio-Ectosone 0.1% Scalp Lotion (DIN 00653217) manufactured by Teva Canada Limited, Betaderm 0.1% Scalp Lotion (DIN 00716634) manufactured by Taro Pharmaceuticals Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Teva Canada Limited has advised Alberta Blue Cross that the shortage of Ratio-Ectosone 0.1% Scalp Lotion (DIN 00653217) has been resolved.

As a result, Betaderm 0.1% Scalp Lotion (DIN 00716634) will no longer be considered a temporary benefit for the *ADBL* after **March 1, 2018**.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit www.ab.bluecross.ca/providers/pharmacy-home.php



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.721 2018/02

